11-102047596-A-G
Position:
Variant summary
Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBA1
The NM_032930.3(CFAP300):c.110+16A>G variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.97 in 1,533,484 control chromosomes in the GnomAD database, including 721,938 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).
Frequency
Genomes: 𝑓 0.96 ( 70793 hom., cov: 33)
Exomes 𝑓: 0.97 ( 651145 hom. )
Consequence
CFAP300
NM_032930.3 intron
NM_032930.3 intron
Scores
2
Clinical Significance
Conservation
PhyloP100: -0.157
Genes affected
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -20 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.84).
BP6
Variant 11-102047596-A-G is Benign according to our data. Variant chr11-102047596-A-G is described in ClinVar as [Benign]. Clinvar id is 1192590.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (EAS) allele frequency at 95% confidence interval = 0.977 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFAP300 | NM_032930.3 | c.110+16A>G | intron_variant | ENST00000434758.7 | NP_116319.2 | |||
CFAP300 | NM_001363505.2 | c.110+16A>G | intron_variant | NP_001350434.1 | ||||
CFAP300 | NM_001195005.2 | c.110+16A>G | intron_variant | NP_001181934.1 | ||||
CFAP300 | XM_005271713.5 | c.110+16A>G | intron_variant | XP_005271770.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CFAP300 | ENST00000434758.7 | c.110+16A>G | intron_variant | 2 | NM_032930.3 | ENSP00000414390.2 | ||||
CFAP300 | ENST00000534360.1 | c.110+16A>G | intron_variant | 1 | ENSP00000435482.1 | |||||
CFAP300 | ENST00000530659.1 | n.129A>G | non_coding_transcript_exon_variant | 1/6 | 1 | |||||
CFAP300 | ENST00000526781.5 | c.110+16A>G | intron_variant | 3 | ENSP00000433074.1 |
Frequencies
GnomAD3 genomes AF: 0.964 AC: 146722AN: 152206Hom.: 70737 Cov.: 33
GnomAD3 genomes
AF:
AC:
146722
AN:
152206
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.971 AC: 134141AN: 138130Hom.: 65142 AF XY: 0.972 AC XY: 72751AN XY: 74828
GnomAD3 exomes
AF:
AC:
134141
AN:
138130
Hom.:
AF XY:
AC XY:
72751
AN XY:
74828
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.971 AC: 1341102AN: 1381160Hom.: 651145 Cov.: 33 AF XY: 0.971 AC XY: 662055AN XY: 681722
GnomAD4 exome
AF:
AC:
1341102
AN:
1381160
Hom.:
Cov.:
33
AF XY:
AC XY:
662055
AN XY:
681722
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.964 AC: 146836AN: 152324Hom.: 70793 Cov.: 33 AF XY: 0.965 AC XY: 71852AN XY: 74484
GnomAD4 genome
AF:
AC:
146836
AN:
152324
Hom.:
Cov.:
33
AF XY:
AC XY:
71852
AN XY:
74484
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:4
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:3
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 31, 2024 | - - |
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
Benign, criteria provided, single submitter | clinical testing | GeneDx | May 10, 2021 | - - |
Ciliary dyskinesia, primary, 38 Benign:1
Benign, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jul 14, 2021 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at